checkAd

     491  0 Kommentare Targovax presents ONCOS-102 scientific rationale at the European Society of Gene and Cell Therapy - Seite 2

    Malignant mesothelioma is a rare type of cancer often caused by exposure to asbestos. There are no curative treatments although surgery, chemotherapy and radiotherapy can sometimes help to improve patient prognosis and life expectancy. Pemetrexed and cisplatin is the only standard of care chemotherapy for malignant mesothelioma, but the median PFS/OS (progression-free survival/overall survival) from the initiation of treatment is only approximately 12 months. There is therefore a significant medical need to develop more effective treatments.

    For further information, please contact:
    Gunnar Gårdemyr, CEO
    Phone: +46 73 083 77 79
    Email: ggardemyr@targovax.com

    Øystein Soug, CFO
    Phone: +47 90 6565 25
    Email: oystein.soug@targovax.com

    Media and IR enquires:
    Jan Petter Stiff - Crux Advisers (Norway)
    Phone: +47 995 13 891
    Email: stiff@crux.no

    Julia Phillips/Simon Conway - FTI Consulting (International)
    Phone: +44 20 3727 1000
    Email: Targovax@fticonsulting.com

    About Targovax

    Arming the patient's immune system to fight cancer

    Targovax (OSE: TRVX) is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aims to become a world leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology.

    ONCOS-102 is a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment is designed to reactivate the immune system's capacity to recognize and attack cancer cells.

    TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, 50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.

    These product candidates will be developed in combination with multiple treatments, including checkpoint inhibitors in several cancer indications. Targovax also has a number of other cancer immune therapy candidates in the early stages of development.

    In July 2016 the Company listed its shares on Oslo Axess, securing funding for further development of the Company's ongoing and planned trials.

    This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.



    This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Targovax ASA via Globenewswire

    Seite 2 von 2



    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Targovax presents ONCOS-102 scientific rationale at the European Society of Gene and Cell Therapy - Seite 2 Studies to date have shown the ability of ONCOS-102 to immune activate patients with treatment refractory malignant mesothelioma at lesional level Oslo, 21th October, 2016: Targovax, a clinical stage company focused on developing and …